Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, Nyxol License Agreement (Details)

v3.23.3
License and Collaboration Agreements, Nyxol License Agreement (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 25, 2023
USD ($)
Nov. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Performanceobligation
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Performanceobligation
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Nov. 06, 2022
USD ($)
Collaboration and License Agreement [Abstract]                
Milestone payments reflected as accounts receivable     $ 10,132,000   $ 10,132,000   $ 1,298,000  
Revenue recognized     11,935,000 $ 0 17,358,000 $ 0    
Reconciliation of Closing Balance of Contract Asset [Abstract]                
Beginning Balance         3,552,000      
Revenue recognized     11,935,000 $ 0 17,358,000 $ 0    
Ending Balance     $ 1,211,000   $ 1,211,000      
Nyxol License Agreement [Member]                
Collaboration and License Agreement [Abstract]                
Non-refundable cash payment received   $ 35,000,000            
Maximum amount of payments receivable for development, regulatory and commercial milestones               $ 130,000,000
Milestone payments to be received               $ 10,000,000
Maximum percentage of tiered royalties receivable     20.00%   20.00%      
Number of distinct performance obligations | Performanceobligation     2   2      
Aggregate transaction price to be recognized $ 10,000,000       $ 40,000,000      
Period of non-cancellation window agreement         120 days      
Non-cancellation period of constrained         120 days      
Milestone payment requirements attributed to the FDA's approval $ 10,000,000              
Milestone payment included in revenue recognition     $ 10,000,000   $ 10,000,000      
Milestone payments reflected as accounts receivable     10,000,000   10,000,000      
Revenue recognized     11,900,000   17,358,000      
Reconciliation of Closing Balance of Contract Asset [Abstract]                
Beginning Balance         3,552,000      
Revenue recognized     11,900,000   17,358,000      
Ending Balance     1,211,000   1,211,000      
Nyxol License Agreement [Member] | License Transfer Fee [Member]                
Collaboration and License Agreement [Abstract]                
Aggregate transaction price to be recognized         35,000,000      
Estimated standalone selling price for license agreement         287,800,000      
Transaction price allocation of ESSP obligations         39,300,000      
Reconciliation of Closing Balance of Contract Asset [Abstract]                
Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement         (19,699,000)      
Nyxol License Agreement [Member] | Research and Development Services [Member]                
Collaboration and License Agreement [Abstract]                
Aggregate transaction price to be recognized         5,000,000      
Estimated standalone selling price for license agreement         5,000,000      
Transaction price allocation of ESSP obligations         700,000      
Nyxol License Agreement [Member] | Sales Milestones [Member]                
Collaboration and License Agreement [Abstract]                
Milestone payment requirements attributed to the FDA's approval     $ 10,000,000   10,000,000      
Revenue recognized         0      
Reconciliation of Closing Balance of Contract Asset [Abstract]                
Revenue recognized         $ 0